Iodine-124 PET is an useful 3-dimensional imaging technique for diagnosis and management of thyroid diseases. The difficulty in interpretation of the PET scans with highly selective tracers like iodine-124, is the lack of identifiable anatomical structures, so an accurate anatomical localization of foci presenting abnormal uptake is problematic. Consequently, a combined PET/CT scanner can resolve these difficulties by co-registering PET and CT data in a single session allowing a correlation of functional and morphologic imaging.
BRIEF REPORT
A 54-year-old male with a history of an well differentiated (G1) follicular thyroid carcinoma (1cm in diameter penetration of the thyroid capsule; pT4 pN0 MX) was referred to the Department of Nuclear Medicine for radioiodine therapy. The medical history was inconspicuous. The physical examination showed a patient in good general condition. On admission time the following pathologic laboratory values were seen: Thyreoglobulin: 1.8 ng/ml, recovery test: 68%, thyroid stimulating hormone: 68 mU/l, fT3 <2.9 ng/ml and fT4 2.8 ng/ml. Cervical ultrasonography showed no pathological structures. Prior to further treatment, an accurate staging was desired.
IODINE-124 PET/CT
24 hours after the oral administration of 85 MBq of the positron-emitting radionuclide [iodine-124]-sodium-iodide [ 1 ] images on a combined PET/CT system were acquired (biograph, Siemens Medical Solutions Erlangen, Germany manufactured by CPS, Knoxville, USA). Projections from head to pelvis were obtained. The biograph consists of a single slice spiral CT (Somaton Emotion) and a dedicated full-ring PET scanner (ECAT HR+). The CT data are also used for PET attenuation correction in a 3D mode [ 2 , 3 ] . The PET scan alone showed pathologically increased tracer uptake in two cervically or mediastinal foci ( Fig. 1, left) . An accurate anatomical localization of these foci was not completely possible as the tracer is highly specific. The CT scan alone showed no pathology. Image fusion of PET and the co-registrated CT enabled to attribute the pathological tracer uptake to an area close to the aorta representing mediastinal micrometastases.
IODINE-131 SCAN
Iodine-131 Scan; Eight days after the oral administration of the therapeutic dose of 3,000 MBq Iodine-131 a whole body scan was acquired (Bodyscan, Siemens Erlangen, Germany) using a high energy collimator. Pathological tracer uptake was documented cervically and mediastinally Another positron emitter suitable for PET imaging is iodine-124 with a half-life of 4.2 days. It has not been widely used because of a complex decay scheme including several high energy gamma rays [1, 9 , 10 , 11 , 12 ]. This 3-dimensional imaging technique has been shown to be an useful imaging technique for diagnosis and management of thyroid diseases [11] . However, the difficulty in interpretation of the PET scans with highly selective tracers like iodine-124, is the lack of identifiable anatomical structures [2] . The low anatomical resolution of the presented PET scan is insufficient for an accurate anatomical localization of foci with abnormal uptake (Fig. 1, right) . In our case, the use of a combined PET/CT system provided accurately fused PET and CT images in a single session [2] [3] . Fused images revealed mediastinal micrometastases of the thyroid carcinoma. Accurate metabolical and anatomical staging was therefore accomplished. Compared to iodine-131 whole body scan, iodine-124 PET/CT has shown to be superior in exact localisation of metastases. 
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